- Home
- SGU vs EOLS Comparison
SGU vs EOLS Comparison
Compare SGU & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- EOLS
- Stock Information
- Founded
- SGU 1995
- EOLS 2012
- Country
- SGU United States
- EOLS United States
- Employees
- SGU N/A
- EOLS N/A
- Industry
- SGU Other Specialty Stores
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- EOLS Health Care
- Exchange
- SGU Nasdaq
- EOLS Nasdaq
- Market Cap
- SGU 390.2M
- EOLS 406.9M
- IPO Year
- SGU 1995
- EOLS 2018
- Fundamental
- Price
- SGU $11.98
- EOLS $6.50
- Analyst Decision
- SGU
- EOLS Strong Buy
- Analyst Count
- SGU 0
- EOLS 4
- Target Price
- SGU N/A
- EOLS $21.25
- AVG Volume (30 Days)
- SGU 37.0K
- EOLS 1.0M
- Earning Date
- SGU 08-06-2025
- EOLS 11-05-2025
- Dividend Yield
- SGU 6.24%
- EOLS N/A
- EPS Growth
- SGU 33.71
- EOLS N/A
- EPS
- SGU 1.66
- EOLS N/A
- Revenue
- SGU $1,777,057,000.00
- EOLS $277,941,000.00
- Revenue This Year
- SGU N/A
- EOLS $13.68
- Revenue Next Year
- SGU N/A
- EOLS $27.96
- P/E Ratio
- SGU $7.14
- EOLS N/A
- Revenue Growth
- SGU N/A
- EOLS 17.15
- 52 Week Low
- SGU $10.84
- EOLS $5.71
- 52 Week High
- SGU $13.75
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- SGU 62.64
- EOLS 44.47
- Support Level
- SGU $11.61
- EOLS $6.08
- Resistance Level
- SGU $11.98
- EOLS $6.55
- Average True Range (ATR)
- SGU 0.18
- EOLS 0.21
- MACD
- SGU 0.04
- EOLS 0.06
- Stochastic Oscillator
- SGU 96.72
- EOLS 70.42
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.